Imvax Advances a New Approach to Personalized Cancer Immunotherapy
**Sponsored Content**
Learn more about Imvax’s Phase 2b trial studying a personalized, whole tumor-derived immunotherapy in newly diagnosed patients with glioblastoma.
**Sponsored Content**
Learn more about Imvax’s Phase 2b trial studying a personalized, whole tumor-derived immunotherapy in newly diagnosed patients with glioblastoma.
On November 17, 2022, results from a phase 3 trial of DCVax-L, an immunotherapy for glioblastoma patients, were published in the Journal of the American Medical Association (JAMA) Oncology.
American Brain Tumor Association
8550 W. Bryn Mawr Ave. Ste 550
Chicago, IL 60631
